老年养老院居民联用曲马多与抗抑郁药与癫痫发作风险
这项基于美国医保养老院人群的队列研究纳入约7万例老年长期居民,发现曲马多联用CYP2D6抑制性抗抑郁药较联用CYP2D6中性抗抑郁药的癫痫发作发生率比值升高(调整后IRR分别为1.09和1.06),提示临床需关注该联用的癫痫风险。
要点
- 老年养老院居民曲马多联用CYP2D6抑制性抗抑郁药,癫痫发作风险高于联用CYP2D6中性抗抑郁药。
- 两个用药启动亚组均显示风险升高,调整后IRR分别为1.09(95%CI 1.02-1.18)和1.06(95%CI 1.03-1.10)。
- 临床对使用曲马多的老年患者,应警惕尤其联用CYP2D6抑制性抗抑郁药时的癫痫风险。
核心结论
- 老年养老院居民中,曲马多联用CYP2D6抑制性抗抑郁药较联用CYP2D6中性抗抑郁药与更高的癫痫发作风险相关。
研究设计与样本
- 纳入在已有曲马多治疗中启动抗抑郁药者,或在已有抗抑郁药治疗中启动曲马多者,随访至1年、出院、死亡或研究结束。
主要发现
- 共识别11,162例曲马多-抗抑郁药用户(平均年龄86.2岁,女性81.3%)和58,994例抗抑郁药-曲马多用户(平均年龄85.3岁,女性79.8%)。
- 曲马多-抗抑郁药组和抗抑郁药-曲马多组的癫痫发生率分别为每100患者年16.10和20.17。
- 两亚组中,曲马多联用CYP2D6抑制性(对比CYP2D6中性)抗抑郁药的调整后癫痫发生率比值分别为1.09(95%CI 1.02-1.18)和1.06(95%CI 1.03-1.10)。
- 阴性对照暴露分析显示氢可酮联用CYP2D6抑制性(对比CYP2D6中性)抗抑郁药与癫痫风险无关。
关键数值与推荐
- 曲马多-抗抑郁药组:联用CYP2D6抑制性抗抑郁药的调整后IRR为1.09(95%CI 1.02-1.18)。
- 抗抑郁药-曲马多组:联用CYP2D6抑制性抗抑郁药的调整后IRR为1.06(95%CI 1.03-1.10)。
临床怎么用
- 临床医生应警惕老年患者曲马多联用抗抑郁药时的癫痫风险,尤其联用CYP2D6抑制性抗抑郁药时。
局限性
- 研究结果仅可推广至长期养老院人群。
- 研究存在残留混杂的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Concomitant use of tramadol and antidepressants with potent inhibition of the cytochrome P450 2D6 (CYP2D6) enzyme is postulated to increase risk of seizures in older adults; yet, such an association has not been empirically tested in populations. We aimed to examine the association of concomitant tramadol and CYP2D6-inhibiting vs CYP2D6-neutral antidepressant use and the risk of seizures among older nursing home (NH) residents. METHODS: This population-based cohort study was conducted using a 100% Medicare NH sample from January 2010 to December 2021. We included long-term residents aged 65 years or older who initiated antidepressants on existing tramadol use (tramadol-antidepressant users) or initiated tramadol on existing antidepressant use (antidepressant-tramadol users). Patients were followed up until the end of 1 year, NH discharge, death, or study end. The key exposure was concomitant use of tramadol with CYP2D6-inhibiting vs CYP2D6-neutral antidepressants. The key outcome was incident rates of medical encounters with a diagnosis of seizure and analyzed using negative binomial or Poisson regression models adjusted for baseline covariates (e.g., pain status and depressive, physical, and cognitive function) through the inverse probability of treatment weighting. RESULTS: We identified 11,162 concomitant tramadol-antidepressant users (mean [SD] age, 86.2 [8.5] years; 9,077 [81.3%] female) and 58,994 concomitant antidepressant-tramadol users (mean [SD] age, 85.3 [8.4] years; 47,053 [79.8%] female). The incidence rate of seizures was 16.10 and 20.17 per 100 patient-years, respectively, for the tramadol-antidepressant and antidepressant-tramadol group. In both subgroups, co-use of tramadol with CYP2D6-inhibiting (vs with CYP2D6-neutral) antidepressants was associated with higher adjusted incidence rate ratios of seizures (1.09 [95% CI 1.02-1.18] and 1.06 [95% CI 1.03-1.10]). Findings were corroborated by a negative control exposure analysis in which co-use of hydrocodone with CYPD2D6-inhibiting (vs CYP2D6-neutral) antidepressants was not associated with risk of seizures. DISCUSSION: Concomitant use of tramadol with CYP2D6-inhibiting vs CYP2D6-neutral antidepressants was associated with increased risk of seizures. Findings are only generalizable to long-term NH populations and are subject to residual confounding. Clinicians should be mindful of seizure risk in older patients who use tramadol concomitantly with antidepressants, particularly CYP2D6-inhibiting antidepressants. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the combination of tramadol and CYP2D6-inhibiting antidepressants is associated with a higher risk of seizures compared with the combination of tramadol and CYP2D6-neutral antidepressants.
引用
- Wei YJ, Winterstein AG, Schmidt S, et al. Risk of Seizure Associated With Concomitant Use of Tramadol and Antidepressants in Older Nursing Home Residents. Neurology. 2025. PMID: 41061201. doi:10.1212/WNL.0000000000214270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。